Sponsor & Developer Portfolio
Vaxcyte
Clinical development pipeline, platform architecture, and registered trial tracking for Vaxcyte vaccine candidates.
4
Candidates
3
Target Diseases
5
Linked Studies
Development Phase Distribution
Phase 3 Clinical Trial: 2 Phase 2 Clinical Trial: 1 Phase 1 Clinical Trial: 1
Platform Technologies
Biological (unspecified platform): 3 Conjugate vaccine: 1
Target Pathogens & Indications
Group A Streptococcal Infection Invasive pneumococcal disease (31-valent conjugate) Pneumococcal disease
Vaccine Pipeline Candidates (4)
Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.
Phase 1 Clinical Trial
ctgov-placebo-vaxcyte-inc
VAX-A1 Low
Target: Group A Streptococcal Infection
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2027-12 (registry estimate)
Phase 2 Clinical Trial
ctgov-0-5-ml-of-the-low-dose-vax-31-vaxcyte-inc
0.5 mL of the low dose VAX-31
Target: Pneumococcal disease
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2027-12 (registry estimate)
Phase 3 Clinical Trial
ctgov-31-valent-pneumococcal-conjugate-vaccine-vaxcyte-inc
PCV20
Target: Pneumococcal disease
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2027-01 (registry estimate)
Phase 3 Clinical Trial
vax-31-adult
VAX-31 (adult)
Target: Invasive pneumococcal disease (31-valent conjugate)
Platform: Conjugate vaccine
Key Milestone: Topline data from OPUS-1 (company: Q4 2026); planned BLA submission to follow if positive
Explore Other Vaccine Developers & Sponsors
Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.